{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:12:03Z","timestamp":1792613523531,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40266-026-01283-z","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:34:46Z","timestamp":1771407286000},"page":"251-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antiseizure Medications in Older Adults with Epilepsy: Considerations in Pharmacology, Safety, Tolerability, and Effectiveness of Newer Agents"],"prefix":"10.1007","volume":"43","author":[{"given":"Louise M.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Boylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7864","authenticated-orcid":false,"given":"Rani A.","family":"Sarkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"10225","key":"1283_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","volume":"395","author":"A Sen","year":"2020","unstructured":"Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735\u201348.","journal-title":"Lancet"},{"issue":"4","key":"1283_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/14656566.2020.1865311","volume":"22","author":"F Brigo","year":"2021","unstructured":"Brigo F, Lattanzi S. Pharmacotherapeutic considerations for late-onset epilepsy. Expert Opin Pharmacother. 2021;22(4):389\u201391.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1283_CR3","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/epi.13849","volume":"58","author":"MR Schoenberg","year":"2017","unstructured":"Schoenberg MR, Rum RS, Osborn KE, Werz MA. A randomized, double\u2010blind, placebo\u2010controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia. 2017;58(9):1566\u201374.","journal-title":"Epilepsia"},{"issue":"4","key":"1283_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.seizure.2010.12.015","volume":"20","author":"KJ Werhahn","year":"2011","unstructured":"Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Kr\u00e4mer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure. 2011;20(4):305\u201311.","journal-title":"Seizure"},{"issue":"6","key":"1283_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.yebeh.2003.09.007","volume":"4","author":"JA Ferrendelli","year":"2003","unstructured":"Ferrendelli JA, French J, Leppik I, Morrell M, Herbeuval A, Han J, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4(6):702\u20139.","journal-title":"Epilepsy Behav"},{"key":"1283_CR6","unstructured":"US FDA. FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan). 2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr. [Accessed 14 Jan 2026]."},{"issue":"1","key":"1283_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0920-1211(99)00039-X","volume":"37","author":"MJ Brodie","year":"1999","unstructured":"Brodie MJ, Overstall PW, Giorgi L, Group ULES. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 1999;37(1):81\u20137.","journal-title":"Epilepsy Res"},{"issue":"6","key":"1283_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.eplepsyres.2014.04.009","volume":"108","author":"RT Wechsler","year":"2014","unstructured":"Wechsler RT, Leroy R, Van Cott A, Hammer AE, Vuong A, Huffman R, et al. Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. Epilepsy Res. 2014;108(6):1128\u201336.","journal-title":"Epilepsy Res"},{"issue":"11","key":"1283_CR9","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","volume":"64","author":"AJ Rowan","year":"2005","unstructured":"Rowan AJ, Ramsay R, Collins J, Pryor F, Boardman K, Uthman B, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868\u201373.","journal-title":"Neurology"},{"issue":"7","key":"1283_CR10","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1528-1167.2007.01128.x","volume":"48","author":"E Saetre","year":"2007","unstructured":"Saetre E, Perucca E, Isoj\u00e4rvi J, Gjerstad L, Group LS. An international multicenter randomized double\u2010blind controlled trial of lamotrigine and sustained\u2010release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48(7):1292\u2013302.","journal-title":"Epilepsia"},{"key":"1283_CR11","unstructured":"Neurelis, Inc. Neurontin (gabapentin) [package insert]. San Diego (CA): DailyMed; 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388. [Accessed 31 Oct 2025]."},{"issue":"7","key":"1283_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40266-024-01130-z","volume":"41","author":"G Oh","year":"2024","unstructured":"Oh G, Moga DC, Fardo DW, Harp JP, Abner EL. The association of gabapentin initiation with cognitive and behavioral changes in older adults with cognitive impairment: a retrospective cohort study. Drugs Aging. 2024;41(7):623\u201332.","journal-title":"Drugs Aging"},{"key":"1283_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910719","volume":"13","author":"G Oh","year":"2022","unstructured":"Oh G, Moga DC, Fardo DW, Abner EL. The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition. Front Pharmacol. 2022;13:910719.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1283_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193134","volume":"13","author":"JL Fleet","year":"2018","unstructured":"Fleet JL, Dixon SN, Kuwornu PJ, Dev VK, Montero-Odasso M, Burneo J, et al. Gabapentin dose and the 30-day risk of altered mental status in older adults: a retrospective population-based study. PLoS ONE. 2018;13(3):e0193134.","journal-title":"PLoS ONE"},{"key":"1283_CR15","unstructured":"Neurelis, Inc. Pregabalin capsule [package insert]. San Diego (CA): DailyMed; 2025. [Accessed 31 Oct 2025]."},{"issue":"2","key":"1283_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/jcpt.12790","volume":"44","author":"R Mukai","year":"2019","unstructured":"Mukai R, Hasegawa S, Umetsu R, Nakao S, Shimada K, Uranishi H, et al. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases. J Clin Pharm Ther. 2019;44(2):285\u201391.","journal-title":"J Clin Pharm Ther"},{"key":"1283_CR17","first-page":"1","volume":"10","author":"P Klein","year":"2018","unstructured":"Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1\u201322.","journal-title":"Clin Pharmacol"},{"key":"1283_CR18","unstructured":"Neurelis, Inc. Briviact: brivaracetam. San Diego (CA): DailyMed; 2025. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c. [Accessed 31 Oct 2025]."},{"key":"1283_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109922","volume":"158","author":"E Faught","year":"2024","unstructured":"Faught E, Besson H, D\u2019Souza W, Klein P, Reuber M, Rosenow F, et al. Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies. Epilepsy Behav. 2024;158:109922.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1283_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40266-022-00931-4","volume":"39","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, et al. Adjunctive brivaracetam in older patients with focal seizures: evidence from the BRIVAracetam add\u2011on First Italian netwoRk Study (BRIVAFIRST). Drugs Aging. 2022;39(4):297\u2013304.","journal-title":"Drugs Aging"},{"key":"1283_CR21","unstructured":"Prescribing information (PI) for briviact (brivaracetam), subse ction 5.5, \u201cSerious Dermatologic Reactions\u201d 2025. Available from: https:\/\/aesnet.org\/clinical-care\/treatments\/fda-news-and-alerts. [Accessed 13 Feb 2025]."},{"key":"1283_CR22","unstructured":"Neurelis, Inc. Xcopri (cenobamate) [package insert]. San Diego (CA): DailyMed; 2025. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=565c2126-57ae-4e29-b443-723bbe7e2072. [Accessed 31 Oct 2025]."},{"issue":"3","key":"1283_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40266-024-01102-3","volume":"41","author":"R O\u2019Dwyer","year":"2024","unstructured":"O\u2019Dwyer R, Stern S, Wade CT, Guggilam A, Rosenfeld WE. Safety and efficacy of cenobamate for the treatment of focal seizures in older patients: post hoc analysis of a phase III, multicenter, open-label study. Drugs Aging. 2024;41(3):251\u201360.","journal-title":"Drugs Aging"},{"key":"1283_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/epi.18304","volume":"66","author":"GL Krauss","year":"2025","unstructured":"Krauss GL, Sander JW, Rosenfeld WE. Improving the tolerability of antiseizure medications: when and how to use cenobamate and other new antiseizure medications. Epilepsia. 2025;66:15\u201328.","journal-title":"Epilepsia"},{"issue":"1","key":"1283_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.seizure.2017.04.003","volume":"48","author":"A G\u00f3mez-Ib\u00e1\u00f1ez","year":"2017","unstructured":"G\u00f3mez-Ib\u00e1\u00f1ez A, Serratosa J, Guillam\u00f3n E, Garc\u00e9s M, Gir\u00e1ldez B, Toledo M, et al. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: case series. Seizure. 2017;48:53\u20136.","journal-title":"Seizure."},{"issue":"7","key":"1283_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","volume":"108","author":"V Villanueva","year":"2014","unstructured":"Villanueva V, Serratosa J, Guillam\u00f3n E, Garc\u00e9s M, Gir\u00e1ldez B, Toledo M, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108(7):1243\u201352.","journal-title":"Epilepsy Res"},{"issue":"10","key":"1283_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40264-021-01097-5","volume":"44","author":"LM Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es LM, Costa R, Vieira M, Moreira J, Gama H, Soares-da-Silva P. Safety of eslicarbazepine acetate in elderly versus non-elderly patients with focal seizures: from pooled data of clinical studies to 8 years of post-marketing experience. Drug Saf. 2021;44(10):1099\u2013107.","journal-title":"Drug Saf"},{"key":"1283_CR29","unstructured":"Neurelis, Inc. Vimpat: lacosamide tablet. San Diego (CA): DailyMed; 2025. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9e79b42c-38a3-4b2c-a196-a5a1948250e2. [Accessed 31 Oct 2025]."},{"key":"1283_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.yebeh.2019.02.022","volume":"94","author":"C Del Bianco","year":"2019","unstructured":"Del Bianco C, Placidi F, Liguori C, Mari L, Ulivi M, Ornello R, et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: a retrospective study. Epilepsy Behav. 2019;94:178\u201382.","journal-title":"Epilepsy Behav"},{"key":"1283_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2017.04.010","volume":"49","author":"RA Sarkis","year":"2017","unstructured":"Sarkis RA, Nicolas J, Lee JW. Tolerability of lacosamide or zonisamide in elderly patients with seizures. Seizure. 2017;49:1\u20134.","journal-title":"Seizure"},{"key":"1283_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.yebeh.2017.07.045","volume":"75","author":"S Rainesalo","year":"2017","unstructured":"Rainesalo S, M\u00e4kinen J, Raitanen J, Peltola J. Clinical management of elderly patients with epilepsy; the use of lacosamide in a single center setting. Epilepsy Behav. 2017;75:86\u20139.","journal-title":"Epilepsy Behav"},{"key":"1283_CR33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/TCRM.S371396","volume":"18","author":"C-W Huang","year":"2022","unstructured":"Huang C-W, Boonyapisit K, Gunadharma S, Casanova-Gutierrez J, Jin L, Nayak D, et al. Optimal use of perampanel in elderly Asian patients with epilepsy: expert opinion. Ther Clin Risk Manage. 2022;18:825\u201332.","journal-title":"Ther Clin Risk Manage."},{"key":"1283_CR34","unstructured":"Neurelis, Inc. Fycompa (perampanel) [package insert]. San Diego (CA): DailyMed; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=71cf3309-e182-473c-8b0b-280cabd0e122. [Accessed 31 Oct 2025]."},{"key":"1283_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108483","volume":"126","author":"M Maguire","year":"2022","unstructured":"Maguire M, Ben-Menachem E, Patten A, Malhotra M, Ngo LY. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. Epilepsy Behav. 2022;126:108483.","journal-title":"Epilepsy Behav"},{"key":"1283_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122797","volume":"455","author":"A Pascarella","year":"2023","unstructured":"Pascarella A, Gasparini S, Manzo L, Marsico O, Torino C, Abelardo D, et al. Perampanel as only add-on epilepsy treatment in elderly: a subgroup analysis of real-world data from retrospective, multicenter, observational study. J Neurol Sci. 2023;455:122797.","journal-title":"J Neurol Sci"},{"issue":"7","key":"1283_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40266-021-00865-3","volume":"38","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Ciuffini R, Osanni E, Chiesa V, et al. Adjunctive perampanel in older patients with epilepsy: a multicenter study of clinical practice. Drugs Aging. 2021;38(7):603\u201310.","journal-title":"Drugs Aging"},{"key":"1283_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109369","volume":"147","author":"J Wheless","year":"2023","unstructured":"Wheless J, Wechsler RT, Penovich P, Segal E, Chez M, Coppola A, et al. Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: the PERMIT extension study. Epilepsy Behav. 2023;147:109369.","journal-title":"Epilepsy Behav"},{"key":"1283_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","volume":"110","author":"IE Leppik","year":"2015","unstructured":"Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216\u201320.","journal-title":"Epilepsy Res"},{"issue":"2","key":"1283_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.13279","volume":"57","author":"KJ Meador","year":"2016","unstructured":"Meador KJ, Yang H, Pi\u00f1a-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57(2):243\u201351.","journal-title":"Epilepsia"},{"key":"1283_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107514","volume":"115","author":"S-J Ahn","year":"2021","unstructured":"Ahn S-J, Kim T-J, Cha KS, Jun J-S, Byun J-I, Shin Y-W, et al. Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy. Epilepsy Behav. 2021;115:107514.","journal-title":"Epilepsy Behav"},{"key":"1283_CR42","unstructured":"US FDA. Nayzilam (midazolam) approved by FDA. 2019. Available from: https:\/\/www.accessdata.fda.gov\/. [Accessed 31 Oct 2025]."},{"issue":"9","key":"1283_CR43","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"K Detyniecki","year":"2019","unstructured":"Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797\u2013808.","journal-title":"Epilepsia"},{"issue":"1","key":"1283_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","volume":"61","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27\u201335.","journal-title":"Anesthesiology"},{"issue":"6","key":"1283_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0009-9236(99)90084-X","volume":"65","author":"S Albrecht","year":"1999","unstructured":"Albrecht S, Ihmsen H, Hering W, Geisslinger G, Dingemanse J, Schwilden H, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 1999;65(6):630\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1283_CR46","unstructured":"Neurelis, Inc. Valtoco (diazepam) [package insert]. San Diego (CA): DailyMed; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0ddccfe1-0c0d-4290-8ed0-fb20aeb3f7bc. [Accessed 31 Oct 2025]."},{"issue":"2","key":"1283_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/jcph.1726","volume":"61","author":"DJ Greenblatt","year":"2021","unstructured":"Greenblatt DJ, Harmatz JS, Zhang Q, Chen Y, Shader RI. Slow accumulation and elimination of diazepam and its active metabolite with extended treatment in the elderly. J Clin Pharmacol. 2021;61(2):193\u2013203.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1283_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385\u2013407.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"1283_CR49","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1111\/ene.16050","volume":"30","author":"C Dusanter","year":"2023","unstructured":"Dusanter C, Houot M, Mere M, Denos M, Samson S, Herlin B, et al. Cognitive effect of antiseizure medications in medial temporal lobe epilepsy. Eur J Neurol. 2023;30(12):3692\u2013702.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1283_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2006.11.004","volume":"252","author":"M Carter","year":"2007","unstructured":"Carter M, Weaver D, Joudrey H, Carter A, Rockwood K. Epilepsy and antiepileptic drug use in elderly people as risk factors for dementia. J Neurol Sci. 2007;252(2):169\u201372.","journal-title":"J Neurol Sci"},{"issue":"6","key":"1283_CR51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/jgs.15358","volume":"66","author":"H Taipale","year":"2018","unstructured":"Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Tanskanen A, et al. Use of antiepileptic drugs and dementia risk: an analysis of Finnish health register and German health insurance data. J Am Geriatr Soc. 2018;66(6):1123\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1283_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1133816","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jiang H-y, Liu W-J. Anti-seizure medication exposure and the risk of dementia: a meta-analysis of observational studies. Front Neurol. 2023;14:1133816.","journal-title":"Front Neurol"},{"issue":"6","key":"1283_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209820","volume":"103","author":"I Zawar","year":"2024","unstructured":"Zawar I, Kapur J, Mattos MK, Aldridge CM, Manning C, Quigg M. Association of seizure control with cognition in people with normal cognition and mild cognitive impairment. Neurology. 2024;103(6):e209820.","journal-title":"Neurology"},{"issue":"5","key":"1283_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127836","volume":"10","author":"G Zhong","year":"2015","unstructured":"Zhong G, Wang Y, Zhang Y, Zhao Y. Association between benzodiazepine use and dementia: a meta-analysis. PLoS\u00a0One. 2015;10(5):e0127836.","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"1283_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-025-04821-9","volume":"62","author":"K Vakili","year":"2025","unstructured":"Vakili K, Fathi M, Ebrahimi R, Ahmadian S, Moafi M, Ebrahimi MJ, et al. Use of drugs affecting GABAA receptors and the risk of developing Alzheimer\u2019s disease and dementia: a meta-analysis and literature review. Mol Neurobiol. 2025;62(7):1\u201320.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"1283_CR56","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/bcp.15113","volume":"88","author":"A AlDawsari","year":"2022","unstructured":"AlDawsari A, Bushell TJ, Abutheraa N, Sakata S, Al Hussain S, Kurdi A. Use of sedative\u2010hypnotic medications and risk of dementia: a systematic review and meta\u2010analysis. Br J Clin Pharmacol. 2022;88(4):1567\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1283_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2023.0339","volume":"80","author":"XY Tai","year":"2023","unstructured":"Tai XY, Torzillo E, Lyall DM, Manohar S, Husain M, Sen A. Association of dementia risk with focal epilepsy and modifiable cardiovascular risk factors. JAMA Neurol. 2023;80(5):445\u201354.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1283_CR58","doi-asserted-by":"publisher","first-page":"e1686","DOI":"10.1212\/WNL.0000000000010358","volume":"95","author":"C Schnier","year":"2020","unstructured":"Schnier C, Duncan S, Wilkinson T, Mbizvo GK, Chin RF. A nationwide, retrospective, data-linkage, cohort study of epilepsy and incident dementia. Neurology. 2020;95(12):e1686\u201393.","journal-title":"Neurology"},{"issue":"3","key":"1283_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac010","volume":"51","author":"C Dun","year":"2022","unstructured":"Dun C, Zhang Y, Yin J, Su B, Peng X, Liu L. Bi-directional associations of epilepsy with dementia and Alzheimer\u2019s disease: a systematic review and meta-analysis of longitudinal studies. Age Ageing. 2022;51(3):afac010.","journal-title":"Age Ageing"},{"key":"1283_CR60","unstructured":"Science SL. Cenobamate: use in patients with hepatic impairment. 2025. Available from: https:\/\/medicalinfo.sklifescienceinc.com\/search\/documents?searchtext=hepatic&selectProduct=Cenobamate. [Accessed 13 Feb 2026]."},{"key":"1283_CR61","unstructured":"Neurelis, Inc. Aption (eslicarbazepine acetate) [package insert]. San Diego, USA: DailyMed; 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3. [Accessed 31 Oct 2025]."},{"issue":"1","key":"1283_CR62","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2016","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2016;4(1):46.","journal-title":"Eur J Rheumatol"},{"key":"1283_CR63","unstructured":"McCance KL, Huether SE. Pathophysiology: the biologic basis for disease in adults and children. Elsevier Health Sciences, Amsterdam; 2014."},{"key":"1283_CR64","first-page":"1","volume":"405","author":"N Sarafrazi","year":"2021","unstructured":"Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017\u20132018. NCHS Data Brief. 2021;405:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"2","key":"1283_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1212\/WNL.0b013e31825f0466","volume":"79","author":"B Shiek Ahmad","year":"2012","unstructured":"Shiek Ahmad B, Hill KD, O\u2019Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology. 2012;79(2):145\u201351.","journal-title":"Neurology"},{"issue":"8","key":"1283_CR66","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/14740338.2019.1625887","volume":"18","author":"B Miziak","year":"2019","unstructured":"Miziak B, Chro\u015bci\u0144ska-Krawczyk M, Czuczwar SJ. An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs. Expert Opin Drug Saf. 2019;18(8):679\u201389.","journal-title":"Expert Opin Drug Saf"},{"key":"1283_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.seizure.2021.01.008","volume":"86","author":"DR Baddoo","year":"2021","unstructured":"Baddoo DR, Mills AA, Kullab RB, Al-Mashat H, Andersen NB, J\u00f8rgensen NR, et al. Metabolic bone disease in patients with epilepsy and the use of antiepileptic drugs: insight from a Danish cross-sectional study. Seizure. 2021;86:29\u201334.","journal-title":"Seizure"},{"issue":"3","key":"1283_CR68","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eplepsyres.2013.06.011","volume":"106","author":"EL Humphrey","year":"2013","unstructured":"Humphrey EL, Morris GE, Fuller HR. Valproate reduces collagen and osteonectin in cultured bone cells. Epilepsy Res. 2013;106(3):446\u201350.","journal-title":"Epilepsy Res"},{"issue":"9","key":"1283_CR69","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792\u2013802.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1283_CR70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cts.13204","volume":"15","author":"SA Greene","year":"2022","unstructured":"Greene SA, Kwak C, Kamin M, Vernillet L, Glenn KJ, Gabriel L, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899\u2013911.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1283_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40263-024-01137-5","volume":"39","author":"Y Novitskaya","year":"2025","unstructured":"Novitskaya Y, Schulze-Bonhage A, Sch\u00fctz E, Hirsch M. Effects of one-year anti-seizure treatment with add-on cenobamate on bone density and bone turnover in adults with drug-resistant focal epilepsy: an observational study. CNS Drugs. 2025;39(1):95\u2013106.","journal-title":"CNS Drugs"},{"key":"1283_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107550","volume":"113","author":"EK Acton","year":"2020","unstructured":"Acton EK, Gelfand MA, Hennessy S, Xie SX, Pollard JR, Kasner SE, et al. Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010\u20132018. Epilepsy Behav. 2020;113:107550.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1283_CR73","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/sj.bjp.0706830","volume":"149","author":"S Eyal","year":"2006","unstructured":"Eyal S, Lamb J, Smith\u2010Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The antiepileptic and anticancer agent, valproic acid, induces P\u2010glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149(3):250\u201360.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1283_CR74","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/j.1476-5381.2009.00634.x","volume":"159","author":"X Jing","year":"2010","unstructured":"Jing X, Liu X, Wen T, Xie S, Yao D, Liu X, et al. Combined effects of epileptic seizure and phenobarbital induced overexpression of P\u2010glycoprotein in brain of chemically kindled rats. Br J Pharmacol. 2010;159(7):1511\u201322.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1283_CR75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","volume":"76","author":"T Giessmann","year":"2004","unstructured":"Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, et al. Carbamazepine regulates intestinal P\u2010glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76(3):192\u2013200.","journal-title":"Clin Pharmacol Ther"},{"key":"1283_CR76","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","volume":"126","author":"C St\u00f6llberger","year":"2016","unstructured":"St\u00f6llberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98\u2013101.","journal-title":"Epilepsy Res"},{"key":"1283_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01067","volume":"9","author":"A Galgani","year":"2018","unstructured":"Galgani A, Palleria C, Iannone LF, De Sarro G, Giorgi FS, Maschio M, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067.","journal-title":"Front Neurol"},{"issue":"46","key":"1283_CR78","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1093\/eurheartj\/ehz657","volume":"40","author":"TJ von Oertzen","year":"2019","unstructured":"von Oertzen TJ, Trinka E, Bornstein NM. Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination. Eur Heart J. 2019;40(46):3800\u20131.","journal-title":"Eur Heart J"},{"issue":"10","key":"1283_CR79","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376.","journal-title":"Europace"},{"issue":"8","key":"1283_CR80","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaneurol.2024.2057","volume":"81","author":"EK Acton","year":"2024","unstructured":"Acton EK, Hennessy S, Gelfand MA, Leonard CE, Bilker WB, Shu D, et al. Direct-acting oral anticoagulants and antiseizure medications for atrial fibrillation and epilepsy and risk of thromboembolic events. JAMA Neurol. 2024;81(8):835\u201344.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1283_CR81","first-page":"245","volume":"3","author":"CP B\u00e9nit","year":"2016","unstructured":"B\u00e9nit CP, Vecht CJ. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. Neurooncol Pract. 2016;3(4):245\u201360.","journal-title":"Neurooncol Pract"},{"issue":"1","key":"1283_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac112","volume":"4","author":"K Seystahl","year":"2022","unstructured":"Seystahl K, Oppong FB, Le Rhun E, Hertler C, Stupp R, Nabors B, et al. Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. Neuro-Oncol Adv. 2022;4(1):vdac112.","journal-title":"Neuro-Oncol Adv"},{"issue":"11","key":"1283_CR83","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2165\/00002512-200320110-00001","volume":"20","author":"MF Mendez","year":"2003","unstructured":"Mendez MF, Lim GT. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20(11):791\u2013803.","journal-title":"Drugs Aging"},{"issue":"4","key":"1283_CR84","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","volume":"16","author":"KA Vossel","year":"2017","unstructured":"Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer\u2019s disease: causes and clinical relevance. Lancet Neurol. 2017;16(4):311\u201322.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1283_CR85","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1528-1167.2006.00554.x","volume":"47","author":"JC Amatniek","year":"2006","unstructured":"Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, et al. Incidence and predictors of seizures in patients with Alzheimer\u2019s disease. Epilepsia. 2006;47(5):867\u201372.","journal-title":"Epilepsia"},{"issue":"12","key":"1283_CR86","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777\u201392.","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"1283_CR87","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ana.24794","volume":"80","author":"KA Vossel","year":"2016","unstructured":"Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer\u2019s disease. Ann Neurol. 2016;80(6):858\u201370.","journal-title":"Ann Neurol"},{"issue":"2","key":"1283_CR88","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1533317508325095","volume":"25","author":"CF Lippa","year":"2010","unstructured":"Lippa CF, Rosso A, Hepler M, Jenssen S, Pillai J, Irwin D. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen. 2010;25(2):149\u201354.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"11","key":"1283_CR89","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","volume":"78","author":"K Vossel","year":"2021","unstructured":"Vossel K, Ranasinghe KG, Beagle AJ, La A, Pook KA, Castro M, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021;78(11):1345\u201354.","journal-title":"JAMA Neurol"},{"key":"1283_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1648064","volume":"16","author":"ZC Wolcott","year":"2025","unstructured":"Wolcott ZC, Freund BE, Tatum WO, Feyissa AM. Antiseizure medications for primary and secondary seizure prevention after stroke. Front Neurol. 2025;16:1648064.","journal-title":"Front Neurol"},{"issue":"3","key":"1283_CR91","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210231","volume":"104","author":"S Misra","year":"2025","unstructured":"Misra S, Wang S, Quinn TJ, Dawson J, Zelano J, Tanaka T, et al. Antiseizure medications in poststroke seizures: a systematic review and network meta-analysis. Neurology. 2025;104(3):e210231.","journal-title":"Neurology"},{"key":"1283_CR92","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.seizure.2018.08.001","volume":"61","author":"F Brigo","year":"2018","unstructured":"Brigo F, Lattanzi S, Zelano J, Bragazzi N, Belcastro V, Nardone R, et al. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis. Seizure. 2018;61:57\u201362.","journal-title":"Seizure."},{"key":"1283_CR93","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2022.07.003","volume":"100","author":"Y Winter","year":"2022","unstructured":"Winter Y, Uphaus T, Sandner K, Klimpe S, von Stuckrad-Barre S, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. Seizure. 2022;100:109\u201314.","journal-title":"Seizure"},{"issue":"10","key":"1283_CR94","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2174\/1570159X21666230616114255","volume":"21","author":"Y-S Chen","year":"2023","unstructured":"Chen Y-S, Lai M-C, Chen T-S, Tseng Y-H, Li YJ, Huang C-W. Effectiveness and safety of lacosamide, a third-generation anti-seizure medication, for poststroke seizure and epilepsy: a literature review. Curr Neuropharmacol. 2023;21(10):2126\u201333.","journal-title":"Curr Neuropharmacol"},{"key":"1283_CR95","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.seizure.2025.01.016","volume":"125","author":"C Yan","year":"2025","unstructured":"Yan C, Liu J, Jiang J, Sun Y, Chen J, Wei K, et al. A non-inferiority randomized controlled study of perampanel versus oxcarbazepine monotherapy for post-stroke epilepsy. Seizure. 2025;125:172\u20138.","journal-title":"Seizure"},{"issue":"3","key":"1283_CR96","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11060-017-2607-5","volume":"135","author":"BK Rasmussen","year":"2017","unstructured":"Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, N\u00f8rg\u00e5rd BM, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I\u2013IV in the the Danish Neuro-Oncology Registry. J Neuro-Oncol. 2017;135(3):571\u20139.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"1283_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2022.13541","volume":"24","author":"J Tatsuoka","year":"2022","unstructured":"Tatsuoka J, Sano E, Hanashima Y, Yagi C, Yamamuro S, Sumi K, et al. Anti-tumor effects of perampanel in malignant glioma cells. Oncol Lett. 2022;24(6):1\u20139.","journal-title":"Oncol Lett"},{"issue":"7","key":"1283_CR98","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.21873\/anticanres.12737","volume":"38","author":"S Izumoto","year":"2018","unstructured":"Izumoto S, Miyauchi M, Tasaki T, Okuda T, Nakagawa N, Nakano N, et al. Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res. 2018;38(7):4361\u20136.","journal-title":"Anticancer Res"},{"issue":"23","key":"1283_CR99","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-24-1849","volume":"30","author":"S Tobochnik","year":"2024","unstructured":"Tobochnik S, Regan MS, Dorotan MK, Reich D, Lapinskas E, Hossain MA, et al. Pilot trial of perampanel on peritumoral hyperexcitability in newly diagnosed high-grade glioma. Clin Cancer Res. 2024;30(23):5365\u201373.","journal-title":"Clin Cancer Res"},{"key":"1283_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110692","volume":"172","author":"M Sadek","year":"2025","unstructured":"Sadek M, Chemali Z, Sarkis RA. Depression in older adults with epilepsy: pathophysiology and management considerations. Epilepsy Behav. 2025;172:110692.","journal-title":"Epilepsy Behav"},{"key":"1283_CR101","volume-title":"FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications","author":"FDA news release","year":"2008","unstructured":"FDA news release. FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications. Washington: Federal Information & News Dispatch, LLC; 2008."},{"issue":"9","key":"1283_CR102","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","volume":"78","author":"P Klein","year":"2021","unstructured":"Klein P, Devinsky O, French J, Harden C, Krauss GL, McCarter R, et al. Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol. 2021;78(9):1118\u201327.","journal-title":"JAMA Neurol"},{"key":"1283_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110557","volume":"172","author":"P Nuthalapati","year":"2025","unstructured":"Nuthalapati P, DeBonis D, Gopaul M, Okafor CM, Orner M, Jimenez AD, et al. Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population. Epilepsy Behav. 2025;172:110557.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1283_CR104","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139.","journal-title":"N Engl J Med"},{"key":"1283_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108997","volume":"138","author":"HN Lemus","year":"2023","unstructured":"Lemus HN, Sarkis RA. Epilepsy care in nursing facilities: knowledge gaps and opportunities. Epilepsy Behav. 2023;138:108997.","journal-title":"Epilepsy Behav"},{"issue":"11","key":"1283_CR106","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1212\/WNL.0000000000201701","volume":"100","author":"A Vary-O'Neal","year":"2023","unstructured":"Vary-O\u2019Neal A, Miranzadeh S, Husein N, Holroyd-Leduc J, Sajobi TT, Wiebe S, et al. Association between frailty and antiseizure medication tolerability in older adults with epilepsy. Neurology. 2023;100(11):e1135\u201347.","journal-title":"Neurology"},{"issue":"1","key":"1283_CR107","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/cont.0000000000001521","volume":"31","author":"BW Abou-Khalil","year":"2025","unstructured":"Abou-Khalil BW. Update on antiseizure medications 2025. Continuum (Minneap Minn). 2025;31(1):125\u201364.","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"1283_CR108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17425255.2022.2075342","volume":"18","author":"G Liparoti","year":"2022","unstructured":"Liparoti G, Burchiani B, Mencaroni E, Tripodi D, Di Cara G, Verrotti A. Individualizing doses of antiepileptic drugs. Expert Opin Drug Metab Toxicol. 2022;18(3):219\u201333.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"15_Suppl.","key":"1283_CR109","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P1.5-034","volume":"92","author":"S Greene","year":"2019","unstructured":"Greene S, Orlinski L, Streicher C, Vernillet L. The pharmacokinetics of cenobamate in special populations (P1. 5-034). Neurology. 2019;92(15_Suppl.):P1.5-034.","journal-title":"Neurology"},{"issue":"6","key":"1283_CR110","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318.","journal-title":"CNS Drugs"},{"issue":"6","key":"1283_CR111","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M, Soares\u2010da\u2010Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935\u201346.","journal-title":"Epilepsia"},{"issue":"12","key":"1283_CR112","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40264-017-0576-4","volume":"40","author":"H Gama","year":"2017","unstructured":"Gama H, Vieira M, Costa R, Gra\u00e7a J, Magalh\u00e3es LM, Soares-da-Silva P. Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience. Drug Saf. 2017;40(12):1231\u201340.","journal-title":"Drug Saf"},{"issue":"3","key":"1283_CR113","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clinthera.2024.01.008","volume":"46","author":"X Zhu","year":"2024","unstructured":"Zhu X, Guo L, Zhang L, Xu Y. Physiologically based pharmacokinetic modeling of lacosamide in patients with hepatic and renal impairment and pediatric populations to support pediatric dosing optimization. Clin Ther. 2024;46(3):258\u201366.","journal-title":"Clin Ther"},{"key":"1283_CR114","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40262-013-0107-0","volume":"53","author":"GD Anderson","year":"2014","unstructured":"Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet. 2014;53:29\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"1283_CR115","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.eplepsyres.2015.03.005","volume":"113","author":"A Laurenza","year":"2015","unstructured":"Laurenza A, Yang H, Williams B, Zhou S, Ferry J. Absence of liver toxicity in perampanel-reated subjects: pooled results from partial seizure phase III perampanel clinical studies. Epilepsy Res. 2015;113:76\u201385.","journal-title":"Epilepsy Res"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01283-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:03:00Z","timestamp":1773802980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01283-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01283-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Louise McCarthy and Kelly A. Boylan have no conflicts of interest that are directly relevant to the content of this article. Rani Sarkis has received consultant fees from UCB Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LMC and KAB: contributed to the conception and design of the work, drafting the initial manuscript, and reviewing the final draft of manuscript. RS: contributed to the conception and design of the work, reviewing the manuscript, and approval of final version of the manuscript. All authors have read and approved of the final version of the manuscript and agreed to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}